4 ms·

>it is immediately classified as "reserve antibiotic" and the sale is restricted. Is that so medical professionals can break it out as a means of last resort t

by ac2u 3y ago

>it is immediately classified as "reserve antibiotic" and the sale is restricted. Is that so medical professionals can break it out as a means of last resort to save a patient and ensure the course is finished? If so that mightn't be a bad idea before we destroy the potential of new antibiotics too by having the general public misuse them render them useless over time.

zbrozek 3y ago
It's probably a good idea. But doing that alone--without substituting market incentives with something else--means that there won't be new products to use in that way.
garrisonhh 3y ago
I think the above commenter is just pointing out how the fundamental conflict between these two things results in significantly lessened incentive for pharmaceutical companies to put money into researching new antibiotics
- schneems 3y ago
  I extremely know nothing about this field. Would a naive approach would to have a coordinated “crop rotation” type tactic where all hospitals switched to a primary antibiotic every C years/months do anything?
  - RiDiracTid 3y ago
    Empirically, many bacteria seem to be able to acquire resistance in a way that doesn't significantly impact their fitness, meaning they can basically get new resistances and keep old ones for almost arbitrarily long, so the crop rotation idea would fail massively. https://academic.oup.com/femsre/article/35/5/901/2680377 https://academic.oup.com/femsre/article/35/5/901/2680377
    - schneems 3y ago
      Good to know, thanks for the explanation!
    - Log_out_ 3y ago
      It has costs. Replication gets more expensive and slower, more error prone. Also bacteria exchanges resistance DNA among itself. Would be a cool vector to give them weekness.
zdragnar 3y ago
There's a secondary consideration as well; designing new chemicals is fairly easy, synthesizing them harder, and scaling that to commercial manufacturing very hard. Oh, and you still have to prove it to be safe and effective through years of clinical trials. AI is basically still only helping us with the easiest parts, and this particular class is drugs is essentially a limited resource (to avoid force-evolving stains of bacteria that are resistant or immune). At the end of the day, there's not as much research because there's a finite amount of resources to go around and there are easier / lower hanging fruit.
Log_out_ 3y ago
Restricted? As in used by vetrinarys and cure for all in the poorer parts of the world? Also good if there is something to stop hospital bacteria eating patients in slices. Wish we had a wheel of antibiotics, were resistance makes the bacteria vulnerable to something on the opposite of the wheel.

by ac2u 3y ago

zbrozek 3y ago

It's probably a good idea. But doing that alone--without substituting market incentives with something else--means that there won't be new products to use in that way.

garrisonhh 3y ago

I think the above commenter is just pointing out how the fundamental conflict between these two things results in significantly lessened incentive for pharmaceutical companies to put money into researching new antibiotics

schneems 3y ago
I extremely know nothing about this field. Would a naive approach would to have a coordinated “crop rotation” type tactic where all hospitals switched to a primary antibiotic every C years/months do anything?
- RiDiracTid 3y ago
  Empirically, many bacteria seem to be able to acquire resistance in a way that doesn't significantly impact their fitness, meaning they can basically get new resistances and keep old ones for almost arbitrarily long, so the crop rotation idea would fail massively. https://academic.oup.com/femsre/article/35/5/901/2680377 https://academic.oup.com/femsre/article/35/5/901/2680377
  - schneems 3y ago
    Good to know, thanks for the explanation!
  - Log_out_ 3y ago
    It has costs. Replication gets more expensive and slower, more error prone. Also bacteria exchanges resistance DNA among itself. Would be a cool vector to give them weekness.

zdragnar 3y ago

There's a secondary consideration as well; designing new chemicals is fairly easy, synthesizing them harder, and scaling that to commercial manufacturing very hard. Oh, and you still have to prove it to be safe and effective through years of clinical trials. AI is basically still only helping us with the easiest parts, and this particular class is drugs is essentially a limited resource (to avoid force-evolving stains of bacteria that are resistant or immune). At the end of the day, there's not as much research because there's a finite amount of resources to go around and there are easier / lower hanging fruit.

Log_out_ 3y ago

Restricted? As in used by vetrinarys and cure for all in the poorer parts of the world? Also good if there is something to stop hospital bacteria eating patients in slices. Wish we had a wheel of antibiotics, were resistance makes the bacteria vulnerable to something on the opposite of the wheel.